GFM
MDGL icon

GF Fund Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

GF Fund Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$262K Sell
488
-22
-4% -$11.3K ﹤0.01% 253
2026
Q1 		$267K Buy
510
+65
+15% +$31.1K ﹤0.01% 264
2025
Q4 		$259K Sell
445
-35
-7% -$17.9K ﹤0.01% 269
2025
Q3 		$220K Sell
480
-78
-14% -$29.1K ﹤0.01% 282
2025
Q2 		$169K Hold
558
– – ﹤0.01% 331
2025
Q1 		$185K Buy
558
+100
+22% +$32.9K ﹤0.01% 325
2024
Q4 		$141K Buy
+458
New +$129K ﹤0.01% 311

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GF Fund Management's MDGL Position: Q2 2026 in Review

GF Fund Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 4.3% in Q2 2026, selling an estimated $11.3K and leaving 488 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #253.

GF Fund Management first reported a position in MDGL in Q4 2024 and has held it in 7 quarters since. The position peaked at $267K in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • GF Fund Management held 488 shares of Madrigal Pharmaceuticals worth $262K as of Q2 2026.
  • GF Fund Management sold 22 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $11.3K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #253 holding.
  • GF Fund Management first reported a position in Madrigal Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Madrigal Pharmaceuticals position peaked at $267K in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.